on the disclosure.

Side effects

rightIn addition to the reduced incidence of gastric ulceration, rofecoxib exhibits no effect on bleeding time or platelet aggregation, even at supratherapeutic doses. Aside from these features, rofecoxib exhibits a similar adverse-effect profile to other NSAIDs.

Heart and blood vessels

VIGOR study and publishing controversy

The Vioxx Gastrointestinal Outcomes Research (VIGOR) study led by Claire Bombardier

1.Previous
3.Next